Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, a synthetic biotechnology company, has announced a partnership with the World Wildlife Fund (WWF) to enhance ocean health and reduce the impact of fishing on shark populations. The collaboration aligns with Amyris' commitment to Environmental, Social, and Governance (ESG) goals, as highlighted in its 2021 ESG report. The partnership aims to promote sustainable fishing practices in Ecuador and Peru and will explore eco-friendly ingredients to mitigate ocean ecosystem impacts. This initiative underscores the need for corporate responsibility in biodiversity conservation.
Amyris, Inc. (Nasdaq: AMRS) announced the launch of two new consumer brands: Stripes™ for (peri)menopausal wellness and EcoFabulous™ for Gen-Z beauty. Stripes launched on October 18, 2022, while EcoFabulous debuted on October 20, 2022. Both brands will be available on Amazon in November and in retail stores soon. CEO John Melo reported strong consumer demand and expects a strong end to 2022, continuing to expand Amyris' portfolio, which includes popular brands like Biossance and Pipette.
Amyris, Inc. (Nasdaq: AMRS) announced the inclusion of its brands—Biossance, JVN Hair, and Rose Inc—in Sephora's UK launch on October 17, 2022. This move marks a significant expansion in the UK and is part of a global partnership with Sephora. With ongoing consumer demand for clean beauty products, Amyris has been recognized by Women's Wear Daily as a leading small cap beauty company. The company aims to bolster its offerings and retail presence in the UK and Europe while focusing on operational excellence and reduced costs.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology focused on sustainable consumer products, announced its participation in two investor conferences. The company will engage in fireside chats moderated by equity research analysts, providing updates on its operations. Key events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 AM ET (virtual) and the Piper Sandler Growth Frontiers Conference on September 13 at 3:30 PM CT (in-person, Nashville, TN). Live webcasts and replays of these presentations will be available on Amyris' Investor Relations website.
Amyris reported Q2 2022 core revenue of $65.2 million, a 54% increase year-over-year, fueled by record consumer revenue of $43 million, up 108%. Year-to-date, consumer revenue surged 113%. The company anticipates $50 million in EBITDA improvements for H2 2022 due to cost actions and price increases. A substantial $700 million in funding enhances liquidity for ongoing growth. However, cash operating expenses rose 73.7 million from Q2 2021, leading to a GAAP net loss of $110 million. The firm continues to expand its retail presence globally.
Amyris, a synthetic biotechnology leader, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 3:00 PM PT in Dana Point, CA. Chief Science Officer Sunil Chandran will represent the company during a fireside chat. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, which employs AI and robotics to scale innovation. The company provides sustainable ingredients used in over 20,000 products globally, reaching more than 300 million consumers.
Amyris, Inc. (Nasdaq: AMRS) announced its financial results for Q2 2022 will be shared on August 9, 2022, before market open. A conference call will follow at 6:00 a.m. PT to discuss these results and provide a business update by CEO John Melo and CFO Han Kieftenbeld. Amyris specializes in sustainable ingredients for Clean Health & Beauty and Flavors & Fragrances markets via its proprietary Lab-to-Market™ platform, reaching over 300 million consumers through 20,000 products.
Amyris, Inc. (Nasdaq: AMRS) announced the successful start of fermentation at its new precision fermentation plant in Barra Bonita, Brazil, marking a significant milestone. This facility, featuring five mini-factories, allows the company to produce all 13 market molecules concurrently, responding to rising demand for sustainable ingredients in beauty, health, and wellness. The plant's capacity is fully committed through 2023, enabling efficient supply to customers. COO Eduardo Alvarez praised the team's achievement in completing this state-of-the-art facility during the pandemic.
Amyris, a synthetic biotechnology company listed on Nasdaq as AMRS, will engage in a virtual fireside chat at the Oppenheimer 22nd Annual Consumer Conference on June 14, 2022, at 11:15 am ET. This event highlights Amyris's commitment to sustainable consumption through its Lab-to-Market™ technology platform, which utilizes advanced machine learning and robotics to accelerate innovation in the Clean Health & Beauty and Flavors & Fragrances markets. A webcast will be available on their Investor Relations page.
